Intravenous doxycycline, azithromycin, or both for severe scrub typhus
<p><strong>BACKGROUND:</strong> The appropriate antibiotic treatment for severe scrub typhus, a neglected but widespread reemerging zoonotic infection, is unclear.</p> <p><strong>METHODS:</strong> In this multicenter, double-blind, randomized, controlled tr...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 其他作者: | |
| 格式: | Journal article |
| 語言: | English |
| 出版: |
Massachusetts Medical Society
2023
|
| _version_ | 1826310796207980544 |
|---|---|
| author | Varghese, GM Dayanand, D Gunasekaran, K Kundu, D Wyawahare, M Sharma, N Chaudhry, D Mahajan, SK Saravu, K Aruldhas, BW Mathew, BS Nair, RG Newbigging, N Mathew, A Abhilash, KPP Biswal, M Prasad, AH Zachariah, A Iyadurai, R Hansdak, SG Sathyendra, S Sudarsanam, TD Prakash, JAJ Manesh, A Mohan, A Tarning, J Blacksell, SD Peerawaranun, P Waithira, N Mukaka, M Cheah, PY Peter, JV Abraham, OC Day, NPJ |
| author2 | INTREST Trial Investigators |
| author_facet | INTREST Trial Investigators Varghese, GM Dayanand, D Gunasekaran, K Kundu, D Wyawahare, M Sharma, N Chaudhry, D Mahajan, SK Saravu, K Aruldhas, BW Mathew, BS Nair, RG Newbigging, N Mathew, A Abhilash, KPP Biswal, M Prasad, AH Zachariah, A Iyadurai, R Hansdak, SG Sathyendra, S Sudarsanam, TD Prakash, JAJ Manesh, A Mohan, A Tarning, J Blacksell, SD Peerawaranun, P Waithira, N Mukaka, M Cheah, PY Peter, JV Abraham, OC Day, NPJ |
| author_sort | Varghese, GM |
| collection | OXFORD |
| description | <p><strong>BACKGROUND:</strong> The appropriate antibiotic treatment for severe scrub typhus, a neglected but widespread reemerging zoonotic infection, is unclear.</p>
<p><strong>METHODS:</strong> In this multicenter, double-blind, randomized, controlled trial, we compared the efficacy of intravenous doxycycline, azithromycin, or a combination of both in treating severe scrub typhus. Patients who were 15 years of age or older with severe scrub typhus with at least one organ involvement were enrolled. The patients were assigned to receive a 7-day course of intravenous doxycycline, azithromycin, or both (combination therapy). The primary outcome was a composite of death from any cause at day 28, persistent complications at day 7, and persistent fever at day 5.</p>
<p><strong>RESULTS:</strong> Among 794 patients (median age, 48 years) who were included in the modified
intention-to-treat analysis, complications included those that were respiratory (in 62%), hepatic (in 54%), cardiovascular (in 42%), renal (in 30%), and neurologic (in 20%). The use of combination therapy resulted in a lower incidence of the composite primary outcome than the use of doxycycline (33% and 47%, respectively), for a risk difference of −13.3 percentage points (95% confidence interval [CI], (21.6 to −5.1; P=0.002). The incidence with combination therapy was also lower than that with azithromycin (48%), for a risk difference of −14.8 percentage points (95% CI, −23.1 to −6.5; P<0.001). No significant difference was seen between the
azithromycin and doxycycline groups (risk difference, 1.5 percentage points; 95% CI, −7.0 to 10.0; P=0.73). The results in the per-protocol analysis were similar to those in the primary analysis. Adverse events and 28-day mortality were similar in the three groups.</p>
<p><strong>CONCLUSIONS:</strong> Combination therapy with intravenous doxycycline and azithromycin was a better
therapeutic option for the treatment of severe scrub typhus than monotherapy with either drug alone. (Funded by the India Alliance and Wellcome Trust; INTREST Clinical Trials Registry–India number, CTRI/2018/08/015159.)</p> |
| first_indexed | 2024-03-07T07:58:47Z |
| format | Journal article |
| id | oxford-uuid:470e9e9f-8fa5-4cb9-a54b-8f07b4bf236f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:58:47Z |
| publishDate | 2023 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:470e9e9f-8fa5-4cb9-a54b-8f07b4bf236f2023-09-07T10:04:57ZIntravenous doxycycline, azithromycin, or both for severe scrub typhusJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:470e9e9f-8fa5-4cb9-a54b-8f07b4bf236fEnglishSymplectic ElementsMassachusetts Medical Society2023Varghese, GMDayanand, DGunasekaran, KKundu, DWyawahare, MSharma, NChaudhry, DMahajan, SKSaravu, KAruldhas, BWMathew, BSNair, RGNewbigging, NMathew, AAbhilash, KPPBiswal, MPrasad, AHZachariah, AIyadurai, RHansdak, SGSathyendra, SSudarsanam, TDPrakash, JAJManesh, AMohan, ATarning, JBlacksell, SDPeerawaranun, PWaithira, NMukaka, MCheah, PYPeter, JVAbraham, OCDay, NPJINTREST Trial Investigators<p><strong>BACKGROUND:</strong> The appropriate antibiotic treatment for severe scrub typhus, a neglected but widespread reemerging zoonotic infection, is unclear.</p> <p><strong>METHODS:</strong> In this multicenter, double-blind, randomized, controlled trial, we compared the efficacy of intravenous doxycycline, azithromycin, or a combination of both in treating severe scrub typhus. Patients who were 15 years of age or older with severe scrub typhus with at least one organ involvement were enrolled. The patients were assigned to receive a 7-day course of intravenous doxycycline, azithromycin, or both (combination therapy). The primary outcome was a composite of death from any cause at day 28, persistent complications at day 7, and persistent fever at day 5.</p> <p><strong>RESULTS:</strong> Among 794 patients (median age, 48 years) who were included in the modified intention-to-treat analysis, complications included those that were respiratory (in 62%), hepatic (in 54%), cardiovascular (in 42%), renal (in 30%), and neurologic (in 20%). The use of combination therapy resulted in a lower incidence of the composite primary outcome than the use of doxycycline (33% and 47%, respectively), for a risk difference of −13.3 percentage points (95% confidence interval [CI], (21.6 to −5.1; P=0.002). The incidence with combination therapy was also lower than that with azithromycin (48%), for a risk difference of −14.8 percentage points (95% CI, −23.1 to −6.5; P<0.001). No significant difference was seen between the azithromycin and doxycycline groups (risk difference, 1.5 percentage points; 95% CI, −7.0 to 10.0; P=0.73). The results in the per-protocol analysis were similar to those in the primary analysis. Adverse events and 28-day mortality were similar in the three groups.</p> <p><strong>CONCLUSIONS:</strong> Combination therapy with intravenous doxycycline and azithromycin was a better therapeutic option for the treatment of severe scrub typhus than monotherapy with either drug alone. (Funded by the India Alliance and Wellcome Trust; INTREST Clinical Trials Registry–India number, CTRI/2018/08/015159.)</p> |
| spellingShingle | Varghese, GM Dayanand, D Gunasekaran, K Kundu, D Wyawahare, M Sharma, N Chaudhry, D Mahajan, SK Saravu, K Aruldhas, BW Mathew, BS Nair, RG Newbigging, N Mathew, A Abhilash, KPP Biswal, M Prasad, AH Zachariah, A Iyadurai, R Hansdak, SG Sathyendra, S Sudarsanam, TD Prakash, JAJ Manesh, A Mohan, A Tarning, J Blacksell, SD Peerawaranun, P Waithira, N Mukaka, M Cheah, PY Peter, JV Abraham, OC Day, NPJ Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title | Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title_full | Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title_fullStr | Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title_full_unstemmed | Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title_short | Intravenous doxycycline, azithromycin, or both for severe scrub typhus |
| title_sort | intravenous doxycycline azithromycin or both for severe scrub typhus |
| work_keys_str_mv | AT varghesegm intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT dayanandd intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT gunasekarank intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT kundud intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT wyawaharem intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT sharman intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT chaudhryd intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT mahajansk intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT saravuk intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT aruldhasbw intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT mathewbs intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT nairrg intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT newbiggingn intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT mathewa intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT abhilashkpp intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT biswalm intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT prasadah intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT zachariaha intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT iyadurair intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT hansdaksg intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT sathyendras intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT sudarsanamtd intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT prakashjaj intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT manesha intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT mohana intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT tarningj intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT blacksellsd intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT peerawaranunp intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT waithiran intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT mukakam intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT cheahpy intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT peterjv intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT abrahamoc intravenousdoxycyclineazithromycinorbothforseverescrubtyphus AT daynpj intravenousdoxycyclineazithromycinorbothforseverescrubtyphus |